



Please type or print plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	10/808,336
Filing Date	March 23, 2004
First Named Inventor	Jacques JOLIVET et al.
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	STROMIX-0008

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CJM		6,630,480		Gourdeau et al.	10/7/2003	
		6,747,036		Gourdeau et al.	6/8/2004	
		5,817,667		Chu et al.	10/6/1998	
		5,270,315		Belleau et al.	12/14/1993	
		5,041,449		Belleau et al.	8/20/1991	
		6,350,753		Belleau et al.	2/26/2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
CJM		WO	02/078678			10/10/2002		
		WO	02/076472			10/03/2002		
		WO	00/57861			10/5/2000		
		WO	02/30922			10/5/2000		
		WO	96/07413			3/14/1996		
		WO	92/18517			10/29/1992		

Examiner
Signature

CJM

Date
Considered

3-20-05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark if the English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/806,336
		Filing Date	March 23, 2004
		First Named Inventor	Jacques JOLIVET et al.
		Group Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	STROMIX-0008
Sheet	2	of	2

OTHER PRIOR ART. -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
cm		International Search Report dated June 17, 2004	
cm		Written Opinion of the International Searching Authority dated March 24, 2004	
cm		Giles F J et al: "Troxacitabine, a novel dioxotane nucleoside analog, has activity in patients with advanced leukemia" Journal of Clinical Oncology, vol. 19, no. 3, 1 February 2001 pages 762-771	
cm		Giles F et al: "Phase II study of Troxatyl in patients with chronic myeloid leukemia in blastic phase (CML-BP)", Blood, W.B. Saunders Company, vol. 98, no. 11, Part 2, 16 november 2001	
cm		Abstract #2633 Antitumor efficacy of troxacitabine given by continuous administration: The human HT-29 colon xenograft used as a tumor model. Proceedings of the American Association for Cancer Research, (1 st Edition) Volume 44, Published March 2003	
cm		Abstract #2633 Antitumor efficacy of troxacitabine given by continuous administration: The human HT-29 colon xenograft used as a tumor model. Proceedings of the American Association for Cancer Research, (2 nd Edition), Volume 44, Published July 2003	
cm		Poster Antitumor efficacy of (Troxatyl) troxacitabine given by continuous administration: The human HT-29 colon xenograft used as a tumor model. AACR Meeting July 2003	
cm		Abstract #553473 Phase I evaluation of troxacitabine (Troxatyl) administered by continuous infusion in patients with refractory acute myeloid leukemia (AML). 45 th ASH Annual Meeting, abstract published August 2003	
cm		Poster Phase I evaluation of troxacitabine (Troxatyl) administered by continuous infusion in patients with refractory acute myeloid leukemia (AML). 45 th ASH Annual Meeting, Dec. 2003	
		Poster	
		Phase I evaluation of troxacitabine administered by continuous infusion in patients with refractory acute myeloid leukemia (AML). ASCO Meeting, June 3-8, 2004	

Examiner Signature		Date Considered	3-20-05
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.